Related Experiment Videos
Another look at two phase I clinical trial designs
1Department of Mathematics, University of California, San Diego, La Jolla, CA 92093-0112, USA.
Statistics in Medicine
|October 16, 1999
Summary
This response corrects previous findings on clinical trial designs. Properly applied, the continual reassessment method (CRM) is safer and faster than standard designs, contrary to prior simulations.
Area of Science:
- Biostatistics
- Clinical Trial Design
- Pharmacometrics
Background:
- A recent paper by Korn et al. compared standard and CRM designs for Phase I trials.
- Korn et al. concluded CRM designs are slower and less safe based on simulations.
- This note challenges those conclusions due to methodological inaccuracies.
Discussion:
- The critique highlights that Korn et al. used a modified CRM, not the standard definition.
- This deviation from the established O'Quigley, Pepe, and Fisher CRM model invalidates their findings.
- The paper re-evaluates the same scenarios using a correctly implemented CRM.
Key Insights:
- Contrary to Korn et al., correctly applied CRM designs are not slower.
- The simulations demonstrate that CRM designs are actually safer than standard approaches.
- The findings challenge established beliefs about CRM design efficiency and safety.
Outlook:
- This work necessitates a re-evaluation of CRM design implementation in clinical trials.
- Accurate application of CRM can lead to more efficient and safer dose-escalation studies.
- Future research should focus on further optimizing and validating CRM methodologies.